All evaluable patients (n=5) demonstrated a significant reduction in Intact Proviral HIV DNA following treatment with AGT103-T.
American Gene Technologies (AGT), a clinical-stage biotechnology company focused on cell and gene therapies for infectious diseases, announced compelling new data from its HIV cure program, AGT103-T, during a late-breaker oral presentation at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda.
The presentation highlighted human clinical data from AGT’s Phase 1 trial evaluating AGT103-T, a cell and gene therapy designed to protect and enhance HIV-specific immune cells. Using a novel, modified Intact Proviral HIV DNA Assay (IPDA) capable of distinguishing vector from viral sequences, AGT reported sustained reductions in intact HIV proviral DNA in all evaluable subjects.
Read the full company press release here.
Source : GLOBE NEWSWIRE
Related HIV and Co-Infections News
-
NIH-funded breakthrough shrinks CRISPR for precision delivery in the body
-
University of Manchester: Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug lenacapavir
-
Medical Xpress: Norway’s ‘Oslo patient’ reaches HIV remission after rare stem cell transplant donated by brother
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.